ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Terminated · Phase 1, Phase 2 · NCT01997840
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $80,694
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 103
About the trial
- Sponsor
- Celgene
- Tested
- ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone (drug)
- Dates
- Started 2014-03-01; completion 2024-02-29
- Results posted
- Yes
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
From ClinicalTrials.gov, last updated 2025-03-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $80,694 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $80,694
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.